BioSpace News Archive

XORTX to Present at “Zoom With LD MICRO”

XORTX Therapeutics Inc., a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces its participation in the Zoom with LD Mirco to be held virtually on March 18, 2021.

March 16, 2021
·
2 min read
Business

Aravive Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Updates

Aravive, Inc., a clinical-stage oncology company developing transformative therapeutics, announced recent corporate updates and financial results for the fourth quarter and full year ended December 31, 2020.

March 16, 2021
·
9 min read
Deals

Logibec Expands into Virtual Care with Ontario-based Acquisition

Logibec Inc. announced that it has entered into an Asset Purchase Agreement to acquire QoC Health, an Ontario-based company.

March 16, 2021
·
2 min read
Business

Remix Therapeutics Appoints Matthew R. Patterson as Executive Chairman of its Board of Directors

Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, announced the appointment of Matthew R. Patterson as Executive Chairman of the company’s Board of Directors.

March 16, 2021
·
2 min read
Business

Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results

Final data from CGT9486 + sunitinib Phase 1/2 study presented at CTOS 2020 demonstrated 12 months median PFS and 20% ORR, including a complete response, in heavily pre-treated advanced GIST patients. Randomized GIST clinical trial initiation expected in 2H21

March 16, 2021
·
8 min read
Drug Development

First Patient Completes Digital Consent with Veeva Clinical Network in Phase 2b Study

Veeva Systems announced that Veeva eConsent, a MyVeeva for Patients application built on Veeva Clinical Network, had its first patient complete an electronic consent for an early phase clinical trial by Crofoot Research Center.

March 16, 2021
·
4 min read
BioMidwest

Spectrum Pharmaceuticals Provides Update on ROLONTIS® (eflapegrastim) Pre-Approval Inspection

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced that the U.S. Food and Drug Administration has scheduled the pre-approval inspection at the ROLONTIS® manufacturing site in May 2021.

March 16, 2021
·
5 min read
Business

Be Bio Announces Appointment of Cell and Gene Therapy Veterans Joanne Smith-Farrell, Ph.D., as Chief Executive Officer and Rick Morgan, Ph.D., as Chief Scientific Officer

-- Adds to a rapidly expanding team committed to pioneering a new class of therapies -- -- Brings demonstrated leadership in business formation and development of cell and gene therapy medicines --

March 16, 2021
·
5 min read
Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma

$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included

March 16, 2021
·
7 min read
Business

NeoGenomics and Elevation Oncology Announce Collaboration to Expand Genomic Testing for NRG1 Fusions Across Solid Tumors in Support of the Phase 2 CRESTONE Study

Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumor Harboring an NRG1 Gene Fusion Identified Using NeoGenomics Advanced Gene Fusion Panels

March 16, 2021
·
8 min read